The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogotá

Mark JM Van Duin; Rafael Conde; Ben Wijnen; Silvia MAA Evers; Javier L. Gonzalez-Rodriguez; Mark JG Govers; Mickaël Hiligsmann

doi:10.1080/14737167.2017.1246185

The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogotá

Mark JM Van Duin
, Rafael Conde
, Ben Wijnen
, Silvia MAA Evers
, Javier L. Gonzalez-Rodriguez
, Mark JG Govers
, Mickaël Hiligsmann

School of Business Administration

Research output: Contribution to Journal › Research Article › peer-review

18 Scopus citations

Abstract

Background: This study aimed to assess the impact of comorbidities (CMs) on costs, utilities and health-related quality of life (HRQOL) among HIV patients in Colombia. Methods: A cross-sectional study was conducted among 138 HIV patients at an outpatient clinic in Bogotá to assess their costs, utilities (EQ5D-5L) and HRQOL (EQ-VAS). CMs and other covariates were gathered from patient records. Multiple regression models were conducted to assess the impact of CMs. Results: Of all patients, 72% experienced CMs; of these, half experienced ≥2 CMs (N = 49). CMs had a statistically significant impact on utilities when the EQ5D-5L (P = 0.022) was applied among patient with ≥2 CMs. No statistical significance was found for the impact of CMs on costs. Conclusion: This study suggests that having multiple CMs significantly influences utility, and CMs have some impact on HRQOL measured using the EQ-VAS but this effect is at the border of significance. No significant impact was observed on costs.

Original language	English (US)
Pages (from-to)	303-310
Number of pages	8
Journal	Expert Review of Pharmacoeconomics and Outcomes Research
Volume	17
Issue number	3
DOIs	https://doi.org/10.1080/14737167.2017.1246185
State	Published - May 4 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Health Policy
Pharmacology (medical)

Access to Document

10.1080/14737167.2017.1246185

Cite this

Van Duin, M. JM., Conde, R., Wijnen, B., Evers, S. MAA., Gonzalez-Rodriguez, J. L., Govers, M. JG., & Hiligsmann, M. (2017). The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogotá. Expert Review of Pharmacoeconomics and Outcomes Research, 17(3), 303-310. https://doi.org/10.1080/14737167.2017.1246185

@article{ee6d05e582414ac6ac3153065777339c,

title = "The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogot{\'a}",

abstract = "Background: This study aimed to assess the impact of comorbidities (CMs) on costs, utilities and health-related quality of life (HRQOL) among HIV patients in Colombia. Methods: A cross-sectional study was conducted among 138 HIV patients at an outpatient clinic in Bogot{\'a} to assess their costs, utilities (EQ5D-5L) and HRQOL (EQ-VAS). CMs and other covariates were gathered from patient records. Multiple regression models were conducted to assess the impact of CMs. Results: Of all patients, 72\% experienced CMs; of these, half experienced ≥2 CMs (N = 49). CMs had a statistically significant impact on utilities when the EQ5D-5L (P = 0.022) was applied among patient with ≥2 CMs. No statistical significance was found for the impact of CMs on costs. Conclusion: This study suggests that having multiple CMs significantly influences utility, and CMs have some impact on HRQOL measured using the EQ-VAS but this effect is at the border of significance. No significant impact was observed on costs.",

author = "\{Van Duin\}, \{Mark JM\} and Rafael Conde and Ben Wijnen and Evers, \{Silvia MAA\} and Gonzalez-Rodriguez, \{Javier L.\} and Govers, \{Mark JG\} and Micka{\"e}l Hiligsmann",

note = "Publisher Copyright: {\textcopyright} 2016 The Author(s). Published by Informa UK Limited, trading as Taylor \& Francis Group.",

year = "2017",

month = may,

day = "4",

doi = "10.1080/14737167.2017.1246185",

language = "English (US)",

volume = "17",

pages = "303--310",

journal = "Expert Review of Pharmacoeconomics and Outcomes Research",

issn = "1473-7167",

publisher = "Taylor and Francis Ltd.",

number = "3",

}

Van Duin, MJM, Conde, R, Wijnen, B, Evers, SMAA, Gonzalez-Rodriguez, JL, Govers, MJG & Hiligsmann, M 2017, 'The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogotá', Expert Review of Pharmacoeconomics and Outcomes Research, vol. 17, no. 3, pp. 303-310. https://doi.org/10.1080/14737167.2017.1246185

TY - JOUR

T1 - The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogotá

AU - Van Duin, Mark JM

AU - Conde, Rafael

AU - Wijnen, Ben

AU - Evers, Silvia MAA

AU - Gonzalez-Rodriguez, Javier L.

AU - Govers, Mark JG

AU - Hiligsmann, Mickaël

PY - 2017/5/4

Y1 - 2017/5/4

N2 - Background: This study aimed to assess the impact of comorbidities (CMs) on costs, utilities and health-related quality of life (HRQOL) among HIV patients in Colombia. Methods: A cross-sectional study was conducted among 138 HIV patients at an outpatient clinic in Bogotá to assess their costs, utilities (EQ5D-5L) and HRQOL (EQ-VAS). CMs and other covariates were gathered from patient records. Multiple regression models were conducted to assess the impact of CMs. Results: Of all patients, 72% experienced CMs; of these, half experienced ≥2 CMs (N = 49). CMs had a statistically significant impact on utilities when the EQ5D-5L (P = 0.022) was applied among patient with ≥2 CMs. No statistical significance was found for the impact of CMs on costs. Conclusion: This study suggests that having multiple CMs significantly influences utility, and CMs have some impact on HRQOL measured using the EQ-VAS but this effect is at the border of significance. No significant impact was observed on costs.

AB - Background: This study aimed to assess the impact of comorbidities (CMs) on costs, utilities and health-related quality of life (HRQOL) among HIV patients in Colombia. Methods: A cross-sectional study was conducted among 138 HIV patients at an outpatient clinic in Bogotá to assess their costs, utilities (EQ5D-5L) and HRQOL (EQ-VAS). CMs and other covariates were gathered from patient records. Multiple regression models were conducted to assess the impact of CMs. Results: Of all patients, 72% experienced CMs; of these, half experienced ≥2 CMs (N = 49). CMs had a statistically significant impact on utilities when the EQ5D-5L (P = 0.022) was applied among patient with ≥2 CMs. No statistical significance was found for the impact of CMs on costs. Conclusion: This study suggests that having multiple CMs significantly influences utility, and CMs have some impact on HRQOL measured using the EQ-VAS but this effect is at the border of significance. No significant impact was observed on costs.

UR - https://www.scopus.com/pages/publications/84992413355

UR - https://www.scopus.com/pages/publications/84992413355#tab=citedBy

U2 - 10.1080/14737167.2017.1246185

DO - 10.1080/14737167.2017.1246185

M3 - Research Article

C2 - 27730842

AN - SCOPUS:84992413355

SN - 1473-7167

VL - 17

SP - 303

EP - 310

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

IS - 3

ER -

The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogotá

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this